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http://www.biomedcentral.com/1471-2407/13/336RESEARCH ARTICLE Open AccessThe cysteinyl leukotriene 2 receptor contributes
to all-trans retinoic acid-induced differentiation of
colon cancer cells
Astrid M Bengtsson2†, Gunilla Jönsson1†, Cecilia Magnusson1, Tavga Salim1, Cecilia Axelsson1 and Anita Sjölander1*Abstract
Background: Cysteinyl leukotrienes (CysLTs) are potent pro-inflammatory mediators that are increased in samples
from patients with inflammatory bowel diseases (IBDs). Individuals with IBDs have enhanced susceptibility to colon
carcinogenesis. In colorectal cancer, the balance between the pro-mitogenic cysteinyl leukotriene 1 receptor
(CysLT1R) and the differentiation-promoting cysteinyl leukotriene 2 receptor (CysLT2R) is lost. Further, our previous
data indicate that patients with high CysLT1R and low CysLT2R expression have a poor prognosis. In this study, we
examined whether the balance between CysLT1R and CysLT2R could be restored by treatment with the cancer
chemopreventive agent all-trans retinoic acid (ATRA).
Methods: To determine the effect of ATRA on CysLT2R promoter activation, mRNA level, and protein level, we
performed luciferase gene reporter assays, real-time polymerase chain reactions, and Western blots in colon cancer
cell lines under various conditions.
Results: ATRA treatment induces CysLT2R mRNA and protein expression without affecting CysLT1R levels.
Experiments using siRNA and mutant cell lines indicate that the up-regulation is retinoic acid receptor (RAR)
dependent. Interestingly, ATRA also up-regulates mRNA expression of leukotriene C4 synthase, the enzyme
responsible for the production of the ligand for CysLT2R. Importantly, ATRA-induced differentiation of colorectal
cancer cells as shown by increased expression of MUC-2 and production of alkaline phosphatase, both of which
could be reduced by a CysLT2R-specific inhibitor.
Conclusions: This study identifies a novel mechanism of action for ATRA in colorectal cancer cell differentiation
and demonstrates that retinoids can have anti-tumorigenic effects through their action on the cysteinyl leukotriene
pathway.
Keywords: All-trans retinoic acid (ATRA), CysLT2R, Leukotriene, Leukotriene receptor, Colon cancer, InflammationBackground
Individuals with inflammatory bowel diseases (IBD) have
a 30-50% increased risk of developing colorectal cancer
[1,2]. The pro-inflammatory cysteinyl leukotrienes
(CysLTs) LTC4, LTD4, and LTE4 are derived from arachi-
donic acid through the actions of 5-lipoxygenase and
leukotriene C4 synthase (LTC4S) [3]. The CysLTs can in-
duce smooth muscle constriction, vascular leakage, and
eosinophil recruitment in inflammatory diseases such as* Correspondence: anita.sjolander@med.lu.se
†Equal contributors
1Department of Laboratory Medicine, Cell and Experimental Pathology, Lund
University, Malmö University Hospital, SE-205 02, Malmö, Sweden
Full list of author information is available at the end of the article
© 2013 Bengtsson et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumasthma and rhinitis (reviewed in [4]). High levels of leu-
kotrienes have been detected in urine from patients with
IBDs including ulcerative colitis and Crohn’s disease
[5,6], and treatment with the 5-lipoxygenase inhibitor
Zileuton significantly alleviates IBD symptoms [7]. Im-
portantly, an increased risk for colorectal cancer has
been observed in IBD patients [2].
CysLT signaling is initiated when a ligand binds one of
the two different G-protein-coupled receptors: CysLT1R,
CysLT2R [8,9]. Activation of the CysLT1R triggers signal-
ing through either or both the Gq- and the Gi-protein
depending on the cell type, most commonly through Gq
[10-12]. We have shown that LTD4 via CysLT1R cantral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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activation that is involved in the regulation of the cal-
cium signal [13,14]. These activities lead to increased
proliferation, survival, and phosphatidylinositol 3-kinase-
and Rac-dependent migration of colorectal cancer cells
[15-17]. In contrast, CysLT2R promotes colorectal cancer
cell differentiation by increasing the activity of the intes-
tinal brush border enzymes alkaline phosphatase and ami-
nopeptidase N [18]. The two receptors also have opposite
functions in mast cells, where CysLT2R negatively regu-
lates the mitogenic responses of CysLT1R [19]. The com-
bination of high CysLT1R expression and low CysLT2R
expression in colon cancer specimens is correlated with
poor survival prognosis and disease outcome [18,20].
Vitamin A (retinol) and its metabolites are commonly
referred to as retinoids. Retinoids play important roles in
embryonic development, vision, and as cancer chemopre-
ventive agents (see review [21,22] ). All-trans retinoic acid
(ATRA) is a potent metabolite of vitamin A and is suc-
cessfully used to treat patients with acute promyelocytic
leukemia [23]. In clinical trials, retinoids have also shown
promising results in head and neck, skin, ovarian, prostate,
and lung cancer [23]. ATRA has also had positive results
in animal models for cancer. For instance, rats on a low-
fat diet supplemented with vitamin A have a reduced
tumor incidence [24]. Moreover, retinoids are effective in
reducing azoxymethane-induced aberrant crypt foci and
colon tumors in rats [25]. ATRA treatment also reduced
tumor growth 40–60% in athymic mice implanted with
HT-29 colon carcinoma cells [26]. In human colon cancer
cell lines, ATRA is capable of inducing growth inhibition,
apoptosis, and differentiation [27].
ATRA exerts its effects through heterodimers of retin-
oic acid receptors (RARs) and retinoid X receptors
(RXRs), which are transcription factors of the nuclear re-
ceptor family [23]. All of the known RAR isoforms (α, β,
and γ) are expressed in colorectal cancer cell lines [28].
The RAR/RXR heterodimers bind constitutively to retin-
oic acid response elements (RAREs) in promoters of
genes; these are characterized by two consensus half
sites [PuG(G/T)TCA] generally arranged as direct re-
peats separated by 2 to 5 nucleotides [23]. Upon ligand
binding, coactivators of the p160 family are recruited to
replace the corepressors SMRT and NCoR, and tran-
scription is initiated [23].
We found sequences in the CysLT2R promoter region
that were identical to RAREs reported in the literature
and hypothesized that treatment of colorectal cancer
cells with ATRA would affect the expression of CysLT2R.
Furthermore, we investigated whether ATRA-induced
colon cancer cell differentiation was dependent on
CysLT2R. LTC4S conjugates LTA4 with glutathione to
form LTC4 [3], and is induced by ATRA in rat basophilic
leukemia cells and associated with subsequent celldifferentiation [29]. In addition to CysLT2R, LTC4S
could be induced by ATRA in colon cancer cells. It is
well established that retinoids are effective inducers of
differentiation in cancer cells, but few studies have
addressed the pathways that mediate these effects.
Methods
Reagents
LTC4 was obtained from Cayman Chemicals Co. (Ann
Arbor, MI); AP 100984 was a gift from Jilly F. Evans (Amira
Pharmaceuticals); and Lipofectamine 2000, Lipofectamine
LTX, and Opti-MEM were from Invitrogen (Carlsbad,
CA). Hybond polyvinylidene difluoride (PVDF) mem-
branes were from Amersham Biosciences (Little Chalfont,
Bucks, UK) and Mini-PROTEAN TGX gels, Immun-blot
PVDF membranes and Immun Star Western C were from
Biorad (Hercules, CA). The rabbit polyclonal CysLT1R
and CysLT2R antibodies were obtained from Innovagen
(Lund, Sweden). The antibodies RARα C-20 (sc-551),
RARβ C-19 (sc-552) and Lamin B C-20 (sc-6216), were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). The secondary peroxidase-conjugated goat anti-
rabbit, rabbit anti-goat and anti-mouse antibodies were
purchased from Dako Cytomation (Glostrup, Denmark).
The caspase-3 fluorometric substrate was obtained from
Upstate (Lake Placid, NY). All other reagents were
obtained from Sigma Chemicals (St Louis, MO).
Cell culture
The colon cancer cell lines Caco-2, SW480 (ATRA-sen-
sitive), and HCT-116 (ATRA-resistant) [30] were grown
in Dulbecco’s modified Eagle medium with 100 μM non-
essential amino acids, RPMI 1640, and McCoy’s 5A
medium, respectively. All media were supplemented
with 10% fetal bovine serum (FBS), 2 mM L-glutamine,
55 IU/mL penicillin, 55 μg/mL streptomycin, and
1.5 μg/mL fungizone (Invitrogen). The cell lines were
kept at 37°C in a humidified atmosphere of 5% CO2 and
95% air. All experiments were performed on day 4–5
after seeding and all ATRA stimulations were performed
in the dark. The cells were left in 1.5% FBS or serum-
free medium overnight to synchronize the cells and were
subsequently treated with 1 or 10 μM ATRA, 40 nM
LTC4, 1 μM AP 100984, and/or 2 mM sodium butyrate
for the time points indicated. Inhibitors were added
30 min before ATRA stimulation. For time courses, all
cells were harvested at the same time.
Western blot
Except for siRNA experiments, whole cell lysates were
used for Western blot analysis of CysLT1R and CysLT2R.
Cells were harvested in Tris lysis buffer on ice
supplemented with 1% (v/v) Triton X-100 and protease
inhibitors and homogenized 10 times with a Dounce
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supernatant was centrifuged at 1000 × g for 5 min to re-
move cell debris. For Western blot experiments analyz-
ing, RARα, and RARβ, a Nuclear Extraction kit (Merck
Millipore) was used according to the supplier’s instruc-
tion and CysLT2R membrane fractions were prepared as
in [18]. The Coomassie/Bradford method (Pierce) was
used to determine protein content, and equivalent protein
amounts for each sample were used. Gel electrophoresis
and immunoblotting was performed as described in [31]
and the blots were scanned in a Molecular Imager
ChemiDoc XRS+with Image Lab software (Biorad). Strip-
ping of the membranes was performed according to the
supplier’s instructions (Re-blot Plus, Merck Millipore) and
reprobed in the same way.
qPCR analysis
Cells for RNA isolation were washed twice in PBS and
immediately frozen at -80°C. The cells were scraped in
the lysis buffer provided in the RNeasy Plus Mini kit
(Qiagen GmbH) and homogenized 10 times with a 20-G
needle. The RNA was isolated and purified according to
the supplier’s instructions. In short, genomic DNA was
removed and RNA was bound to RNeasy spin columns,
washed, and dissolved in RNase-free water. cDNA syn-
thesis was performed using RevertAid H Minus M-
MuLV reverse transcriptase and oligo(dT)18 primers
(Fermentas, Burlington, Canada). The mRNA expression
levels of CysLT1R, CysLT2R, LTC4 synthase, mucin-2
(MUC-2), RARα, and the endogenous reference gene
HPRT-1 were quantified using MaximaTM Probe qPCR
Master Mix (2x) (Fermentas). The cDNA was mixed with
0.9 μM TaqMan primers and master mix and amplified at
60°C in a Mx3005P thermocycler (Stratagene). The follow-
ing Taqman primer sets (Applied Biosystems) were used:
CYSLTR1, Hs00929113_m1; CYSLTR2, Hs00252658_s1;
MUC2, Hs00159374_m1; LTC4S, Hs00168529_m1; RARA,
Hs00940446_m1; RARB, Hs00977140_m1; and HPRT-
1, Hs99999909_m1. The samples were analyzed and
normalized against HPRT-1 using the MxPro software
(Stratagene).
siRNA experiments
Transient siRNA transfections of SW480 cells were car-
ried out according to the manufacturer’s instructions.
Briefly, 3 days after seeding and at approximately 50%
confluence, cells were transfected for 4–6 h in Opti-
MEM with reduced-serum without antibiotics, with a
mixture of Lipofectamine 2000, and 50–100 nM RARα,
RARβ, or control (non-targeting) siRNA. Human RARα
(sc-29465), RARβ siRNA (sc-29466), and control siRNA-
A, -B, and -C (sc-37007, sc-44230, sc-44231 respectively)
were from Santa Cruz Biotechnology and ON-TARGET
plus SMARTpool L-003437-00-0005, L-003438-00-005and ON-TARGETplus Non-Targeting Pool D-001810-10-
05, from Dharmacon. The cells were allowed to rest for at
least 24 h in complete medium, left in 1.5% FBS or serum-
free medium overnight, and stimulated on day 5 as de-
scribed above.Alkaline phosphatase activity
Alkaline phosphatase activity was measured using
disodium p-nitrophenyl phosphate as the substrate.
Caco-2 cells were seeded in Petri dishes and incubated
for 24 h at 37°C in complete Dulbecco’s modified Eagle
medium that was ultraviolet-treated to remove any
traces of endogenous retinoids. ATRA (1 μM) and/or
AP 100984 (1 μM) were added and the cells were incu-
bated for a total of 72 h at 37°C. Every 24 h, the medium
was renewed and ATRA and/or AP 100984 were added
as before. Sodium butyrate (2 mM) was used as a posi-
tive control (data not shown). Five replicates per sample
of scraped and lysed cells (PBS, 0.5% Triton X-100) were
added to a 96-well plate. The alkaline phosphatase activ-
ity was estimated after incubation with disodium p-
nitrophenyl phosphate for 30 min at 37°C by measuring
the absorbance at 405 nm due to formation of p-
nitrophenol. The assay was performed as previously de-
scribed in [32]. The samples were normalized for equal
protein content.ELISA LTC4
SW480 cells were grown for 5 days in normal medium
containing 10% serum after which the medium was
changed to 1.5% serum containing medium and treated
with or without 1 μM ATRA for 24 h. The media were
then collected and separated by solid-phase extraction.
LTC4 from the samples were measured using the LTC4
ELSA kit from Cayman.Thymidine incorporation assay
Five thousand SW480 cells per well were seeded and
cultured for 2 days in flat-bottomed, 96-well plates. Cells
were serum starved overnight and subsequently stimu-
lated for 48 h with 1 μM ATRA in the presence or ab-
sence of 1 μM AP 100984 (CysLT2R inhibitor) or with
medium containing 10% serum as a positive control for
proliferation. Cellular DNA synthesis was assessed by
adding 0.5 μCi 3H-thymidine (GE Healthcare) during the
final 18 h of stimulation. The cells were washed once
with PBS and incubated with 0.05% trypsin-EDTA solu-
tion for 10 min at 37°C. Cells were harvested, collected
on filter paper, and 3H thymidine incorporation was
measured in a 1450 Microbeta Trilux liquid scintillation
counter (Wallac, Turku, Finland).
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SW480 cells were cultured in 6-well plates for 4 days.
Cells were incubated overnight in medium containing
1.5% serum and subsequently stimulated for 48 h with
1 μM ATRA in the presence or absence of 1 μM AP
100984. Taxol (100 nM) was used as a positive control
for apoptosis. The cells were lysed for 15 min on ice in
300 μL buffer containing 1% (v/v) Triton X-100, 10 mM
Tris–HCl (pH 7.4), 10 mM NaH2PO4/Na2HPO4 (pH 7.5),
10 mM sodium pyrophosphate, and 130 mM NaCl. Sam-
ples (50 μL) were suspended in reaction buffer (200 μL
20 mM HEPES, 2 mM dithiothreitol, and 10% glycerol)
and added to Nunc Polysorb 96-well plates where a
caspase-3 fluorometric substrate, Ac-Asp-Glu-Val-Asp-
AMC (3 μL; Upstate), was subsequently added. The plates
were incubated at 37°C for 1 h in the dark, and the fluor-
escence of each well was measured at 390 nm excitation
and 460 nm emission wavelengths using a BMG plate
reader (Offenburg, Germany). Triplicate samples were an-
alyzed and adjusted for equal protein content.
Luciferase reporter assay
A Renilla control reporter plasmid and a pGL3-Enhancer
vector with a luciferase reporter gene containing 1000
base pairs of the CYSLTR2 gene promoter (−1 to-1012)
was used for CysLT2R activity assays [32]. SW480 cells
(5–10 × 104 per well) were seeded in 12-well plates. Cells
were transfected on day 3 with a mixture of the plasmids
and Lipofectamine 2000 or LTX in Opti-MEM according
to the supplier’s instructions. The final DNA amount per
well was 1 μg for the pGL3 plasmid and 50 ng for the
Renilla control vector. When siRNA was co-transfected,
50 nM per well was used. The transfection medium was
changed to complete RPMI 1640 with 10% FBS after 5–
6 h and incubated for 24 h. The medium was changed to
serum-free or serum-low (1.5%) medium and cells were
incubated overnight before stimulation with 10 μM
ATRA. After 48 h of ATRA stimulation, the experiments
were finished by rinsing the wells twice with PBS and
adding passive lysis buffer from the Dual-Luciferase Re-
porter Assay System from Promega (Madison, WI). The
plates were placed on an orbital shaker at a slow rate for
30 min and frozen (−20°C) until analysis. Firefly and
Renilla luminescence were measured on a MiniLumat LB
9506 (Berthold Technologies) according to the protocol
for the Dual-Luciferase Reporter Assay System and the ra-
tio was calculated.
Immunofluorescence
Cells were seeded on glass cover slips and grown for
3 days before being stimulated with 10 μM ATRA for
24 h in the absence of serum. The medium was removed
and after several washes with PBS the cells were fixed
with 4% paraformaldehyde for 15 min and subsequentlypermeabilized with 0.1% Triton X-100 for 5 min. Non-
specific binding was blocked with 3% goat serum in PBS
for 45 min. Cells were incubated with a primary mucin-
2 (MUC-2) antibody (Santa Cruz, diluted 1:50) in 1%
goat serum/PBS for 1 h followed by incubation with a
secondary Alexa-488 antibody (Molecular Probes, di-
luted 1:500) for 1 h at room temperature. After washing
in PBS, the cover slips were mounted on glass slides
with fluorescent mounting medium. Confocal micros-
copy images were recorded using Zeiss LSM 700 (Carl
Zeiss Microscopy GmbH, Jena, Germany).
Statistics
Data was analyzed using PRISM® software (GraphPad
Software Inc., La Jolla, CA). One-way ANOVA; unpaired
one-sample t-test was performed when samples were
compared to a control set to 100% or 1. In all other
cases, an unpaired t-test was performed. Values of P <
0.05 were considered statistically significant.
Results
ATRA treatment increases CysLT2R expression in colon
cancer cells
ATRA is an established differentiation-inducing agent of
epithelial cells [33] and we previously found that
CysLT2R signaling also induces differentiation of colon
cancer cells [18]. When either SW480 or Caco-2 colon
cancer cells were stimulated with 1 μM ATRA, CysLT2R
mRNA was induced 3 h after treatment (Figure 1A
and C). Protein levels of CysLT2R also increased signifi-
cantly, peaking at 3 h in SW480 cells and between 3–12 h
in Caco-2 cells (Figure 1B and D). Because CysLT2R has
been suggested to have opposing activities to those of
CysLT1R, we next investigated the effect of ATRA on
CysLT1R [18,19]. Unlike CysLT2R, which seems to play a
role in differentiation, CysLT1R has mitogenic and pro-
survival effects [15,16]. High CysLT1R expression corre-
lates with poor prognosis of colorectal cancer patients
[20]. We stimulated SW480 cells with 1 μM ATRA for 3–
24 h, but failed to observe an induction in CysLT1R ex-
pression, at either the mRNA or protein level (Figure 1E
and F).
RARα knockdown decreases ATRA-induced CysLT2R
mRNA and protein expression
RARs are nuclear hormone receptors for ATRA, which
upon ligand binding enable the transcription of target
genes [33]. Transfection of SW480 cells with siRNA
against RARα, but not RARβ decreased the induction
of CysLT2R mRNA in response to ATRA stimulation
(Figure 2A). qPCR analysis showed that RARα siRNA
downregulated RARα mRNA levels to approximately
50% (Figure 2B). The mRNA expression of RARβ when






















































































Figure 1 (See legend on next page.)
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Figure 1 CysLT2R expression in ATRA-treated colon cancer cell lines. Cells were incubated for 3, 12, or 24 h in the absence or presence of
1 μM ATRA as indicated. (A and C) qPCR for CysLT2R expression. Data are normalized to HPRT-1 in SW480 and Caco-2 cells. (B and D) Protein
expression of CysLT2R normalized to β-actin in SW480 and Caco-2 cells as determined by Western blot. (E) qPCR for CysLT1R expression in SW480
cells. Data are normalized to HPRT-1. (F) Protein expression of CysLT1R normalized to β-actin in SW480 cells as determined by Western blot.
Changes in CysLT2R expression relative to basal levels in unstimulated cells are shown as mean ± standard error of the mean (SEM; *P < 0.05,
**P < 0.01; n.s. = not significant).
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RARα mRNA to a similar level (data not shown). We
used the nuclear fraction for RARs (Figure 2C) and
membrane fraction for CysLT2R (Figure 2D) protein de-
tection. The induction of CysLT2R protein in the mem-
brane fraction by ATRA was also abolished when
siRNA against RARα was added (Figure 2D). The effect
of siRNA treatment on the respective protein levels was
similar to that observed for the mRNA (i.e., no or little
induction after ATRA stimulation; Figure 2A-D).
To study CysLT2R promoter activity, SW480 cells were
transiently transfected with a luciferase reporter gene
vector and stimulated with ATRA. A dose response was
observed with increasing ATRA concentration (0.1, 1.0,
and 10 μM; Figure 2E). Stimulation with 10 μM ATRA
was chosen for the inhibition studies in which cells were
treated with siRNAs targeting the RARs. Neither RARα
siRNA nor RARβ siRNA induced any significant change
in basal CysLT2R promoter activity (Figure 2F). However,
in contrast to the activation seen for the regulation of the
endogenous CysLT2R gene (Figure 2D), siRNA knock-
down of RARα or RARβ or a combination of the two did
not affect the ATRA-induced activation of the transfected
partial/putative CysLT2R promoter (Figure 2F).ATRA does not affect the proliferation of SW480 colon
cancer cells
The effects of ATRA on tumor suppression cannot be en-
tirely attributed to its role in differentiation, as ATRA has
also been reported to inhibit growth of some colon cancer
cell lines [27,34]. To determine whether ATRA has such
an activity in our system, we pre-incubated SW480 cells
with or without 1 μM CysLT2R antagonist AP 100984 and
stimulated the cells with 1 μM ATRA or 40 nM LTC4 for
48 h. DNA synthesis was measured as the amount of 3H-
thymidine incorporated during the last 18 h of stimulation.
Neither ATRA nor LTC4, alone or in combination, induced
any changes in DNA synthesis compared to unstimulated
cells (Figure 3A). Complete medium with 10% FBS was
used as a positive control for proliferation and induced a
2-fold increase in 3H-thymidine incorporation. These data
showed that neither ATRA nordoes the CysLT2R inhibitor
AP 100984 have any effect on SW480 cell growth.Effects of ATRA on apoptosis, LTC4S mRNA and LTC4
expression in SW480 cells
In some cell types, ATRA induces apoptosis through
the caspase-3 pathway [35]. We therefore investigated
whether ATRA could induce apoptosis in these colon
cancer cells. The cells were incubated with or without
1 μM CysLT2R inhibitor AP 100984 and stimulated
with 1 μM ATRA for 48 h. Under these conditions, we
were unable to observe apoptosis in SW480 cells as
measured by caspase-3 activity (Figure 3B). Taxol was
used as a positive control for apoptosis and induced a
significant (50%) increase in caspase-3 activity. Neither
AP 100984 alone or in combination with ATRA had
any effect on caspase-3 activity, indicating that AP
100984 had no intrinsic apoptotic effect.
We next investigated whether ATRA could increase
LTC4S mRNA expression. Cells were stimulated with
ATRA for 3, 12 or 24 h and the LTC4S mRNA level
was determined with qPCR. We observed a 4-fold in-
crease of LTC4S mRNA in cells treated with ATRA for
12 h compared to control cells (Figure 3C). The induc-
tion of LTC4S can enhance LTC4 production and in
turn induce CysLT2R activation, thus creating a posi-
tive feedback loop that promotes differentiation.
Therefore, we next examined the endogenous synthe-
sis and release of LTC4 in SW480 cells, we found a
basal release of 140 pg/ml LTC4 and a possible en-
hanced release by ATRA to 190 pg/ml LTC4 in SW480
cells (Figure 3D).ATRA does not induce CysLT2R expression in ATRA-
resistant HCT-116 cells
The colon cancer cell line HCT-116 is ATRA-resistant
[34]. We confirmed this with qPCR, finding that stimu-
lation of HCT-116 cells with 1 μM ATRA failed to in-
duce mRNA expression of CysLT2R at any of the time
points observed (Figure 4A). Likewise, Western blots of
lysates harvested from cells treated with 1 μM ATRA
for 3, 12, and 24 h showed there was no effect on
CysLT2R protein expression (Figure 4B). In case the ef-
fect on the protein level was delayed, we also tested
after 48 h of stimulation, but no significant change
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Figure 2 Effect of RARα or RARβ inhibition on CysLT2R expression and promoter activity. SW480 cells were transfected with control siRNA
(non-target siRNA), RARα siRNA, or/and RARβ siRNA, allowed to rest for 24 h, serum-starved overnight, and subsequently stimulated with 10 μM
ATRA. (A and B) qPCR for CysLT2R and RARα expression. Data are normalized to HPRT-1 with and without ATRA stimulation for 3 h. (C) Western
blots without and with ATRA stimulation for 3 h. (D) Western blot analyzes of CysLT2R protein expression in membrane fractions from SW480
cells stimulated or not with ATRA for 3 h normalized to unstimulated control. (E) CysLT2R luciferase promoter activity in cells stimulated with or
without ATRA for 48 h. Data are normalized to unstimulated controls. (F) CysLT2R luciferase promoter activity in siRNA-treated cells stimulated
with or without ATRA for 48 h. Data are normalized to unstimulated control. Values are shown as mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001).
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MUC-2 expression and alkaline phosphatase activity
Mucins are secreted by colonocytes to form a mucus
barrier to protect the intestinal epithelium [36]. MUC-2
is down-regulated in many colorectal cancers and is as-
sociated with the differentiated state of colonic epithelia
[37]. We analyzed the expression of MUC-2 mRNA in
SW480 cells and found that treatment with 1 μM
ATRA increased MUC-2 mRNA expression 2-fold
after 3 h of stimulation (Figure 5A). When cells were
pretreated with 1 μM AP 100984, the ATRA-induced
MUC-2 up-regulation was decreased. AP 100984 itself
had no effect on MUC-2 mRNA expression. Similarly,when cells were treated with RARα siRNA, ATRA-
induced MUC-2 expression was decreased by approxi-
mately 50% (Figure 5B). Thus, ATRA-enhanced MUC-2
expression in SW480 colon cancer cells is at least partly
mediated through CysLT2R and RARα signaling. Fur-
thermore, we also found by immunofluorescence that
the MUC-2 protein expression was increased after
treatment with ATRA for 24 h (Figure 5C).
Alkaline phosphatase is one of the brush border en-
zymes expressed in the differentiated epithelial cells of
the intestines and alkaline phosphatase activity is often
used as a differentiation marker [38]. In accordance with
others’ results from previous studies, we found that
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ase activity in Caco-2 cells, as determined by the forma-
tion of para-nitrophenol (Figure 5D) [39]. Sodium
butyrate was included as a positive control for alkaline
phosphatase activity, and increased the activity approxi-
mately 2-fold compared to unstimulated cells (data not
shown) [40]. Interestingly, ATRA-induced alkaline phos-
phatase activity was significantly reduced upon pretreat-
ment for 30 min with 1 μM CysLT2R inhibitor AP
100984. Addition of the inhibitor alone did not affect
basal alkaline phosphatase activity, suggesting that
ATRA’s induction of alkaline phosphatase activity is
partly mediated through CysLT2R in Caco-2 cells. To-
gether, the MUC-2 expression and alkaline phosphatase
activity studies shows that ATRA’s induction of differen-
tiation is at least partially dependent on CysLT2R
signaling.Figure 3 Effect of ATRA on cell growth, apoptosis, LTC4S and LTC4 ex
100984 (AP) and/or 40 nM LTC4 and were or were not stimulated with 1 μ
treatment, normalized to unstimulated control. (B) Caspase-3 activity after
for LTC4S expression after 3–24 h of ATRA stimulation. Data are normalized
24 h incubation in the absence or presence of ATRA. Values are shown asDiscussion
ATRA is well known to induce differentiation of epithe-
lial cells and we have also shown that CysLT2R induces
differentiation of epithelial cells [23,32]. We found puta-
tive RAREs within the promoter region of the transcrip-
tion start of the CYSLTR2 gene [32]. Based on this
finding, we hypothesized that ATRA could induce
CysLT2R expression. We show here that ATRA can in-
deed induce both mRNA and protein expression of
CysLT2R in two different colon cancer cell lines. Knock-
down of RARα with siRNA decreases ATRA-induced
CysLT2R expression in SW480 cells. In accordance with
this finding, ATRA was unable to induce CysLT2R mRNA
or protein expression in HCT-116 colon cancer cells,
which lack functional RARs. Neither mutations in these
possible response elements nor truncation of the inserted
region changed the cell response to ATRA stimulationpression. SW480 cells were treated with the CysLT2R inhibitor AP
M ATRA. (A) 3H-thymidine incorporation measured after 72 h of ATRA
48 h of ATRA treatment normalized to unstimulated control. (C) qPCR
to HPRT-1. (D) Release of LTC4 into the media form SW480 cells after
















































Figure 4 ATRA does not affect CysLT2R in HCT-116 cells. RAR-mutated HCT-116 colon cancer cells were incubated for 3, 12, or 24 h in the
presence or absence of 1 μM ATRA. (A) qPCR for CysLT2R expression in HCT-116 cells. Data are normalized to HPRT-1. (B) Protein expression of
CysLT2R normalized to β-actin in HCT-116 cells as determined by Western blot. Data show changes in expression relative to basal levels in
unstimulated cells. (n.s. = not significant).
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http://www.biomedcentral.com/1471-2407/13/336(see Additional file 1: Figure S1). Furthermore, a high con-
centration of ATRA is required to observe any cellular re-
sponse. Together, these findings might suggest that
ATRA’s induction of CysLT2R is mediated indirectly or
that the intracellular RAR levels are low. This is in agree-
ment with findings that the relative expression of RARα is
higher than RARβ in human intestine and the overall ex-
pression of RARs (especially RARβ2) is lower in tumors
than normal tissue due to epigenetic modifications [28].
Previous studies showed that CysLT2R can be up-
regulated by the cytokines interferon γ (IFNγ) and
interleukin-4 in monocytes, T cells, and B cells and by
interleukin-13 in monocytes [41,42]. Further, consistent
with its role in inflammatory responses. Bai et al. [43]
have shown that ATRA can down-regulate the colon in-
flammatory response as measured by tumor necrosis fac-
tor alpha (TNFα) levels, in patients with IBD in vitro
and in a murine colitis model in vivo. We previously
found that TNFα also down-regulates CysLT2R while
up-regulating CysLT1R in colon cancer cells [44], an
observation that also highlights the importance of
maintaining receptor balance in epithelial cells [18].
ATRA has previously been shown to induce mRNA
expression, protein expression, and promoter activity ofLTC4S in rat basophilic leukemia cells. LTD4 is a ligand
for CysLT1R that up-regulates both LTC4S and CysLT2R
in intestinal epithelial and colon cancer cells [44]. These
activities are associated with differentiation, but the
underlying signaling mechanism remained unclear [29].
We show for the first time that ATRA is capable of
up-regulating LTC4S mRNA in epithelial cells. LTC4S is
responsible for the production of the cysteinyl leukotri-
ene LTC4. Furthermore, ATRA by inducing both
CysLT2R and possibly its ligand, activates a signaling
pathway that has beneficial effects on colon epithelial
cell differentiation.
MUC-2 and brush border enzymes are typical markers
of differentiated colonocytes [45]. We have previously
shown that LTC4 stimulation of CysLT2R induces differ-
entiation in Caco-2 colon cancer cells, as measured by
increased MUC-2 mRNA expression and increased ac-
tivity of the brush border enzymes alkaline phosphatase
and aminopeptidase N [18]. ATRA has also been shown
to induce MUC-2 protein via PKCα and CREB in airway
human tracheobronchial epithelial cells [46]. Further-
more, rats on a retinoid-deficient diet have decreased
MUC-2 mRNA expression in the jejunum, ileum, and
colon [47]. These studies indicate that ATRA and
A SW480
















































Figure 5 Effect of ATRA on the differentiation markers MUC-2
and alkaline phosphatase activity. SW480 cells were either 1)
treated with 1 μM of the CysLT2R inhibitor AP 100984 (AP) and were
or were not stimulated with 1 μM ATRA or 2) treated with RAR
siRNA and stimulated with 10 μM ATRA. (A and B) qPCR for MUC-2.
Data are normalized to HPRT-1 and changes in MUC-2 expression
are relative to basal levels in untreated cells. (C) Confocal
immunofluorescence microscopy showing ATRA-induced expression
of Mucin-2 in SW480 colon cancer cells. After stimulation with
10 μM ATRA for 24 h the cells were fixed, permeabilized and stained
with a Mucin-2 antibody. Left panels show Mucin-2 (MUC-2)
staining, middle panels nuclear staining with DAPI and right panels
merged, the graphs were taken with 40x objective. (D) Alkaline
phosphatase activity in Caco-2 cells. Bars show % of ATRA-induces
alkaline phosphatase activity and values are shown as mean ± SEM
(*P < 0.05, **P < 0.01).
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ation, as evidenced by MUC-2 expression. In the current
study, we show that ATRA’s ability to induce MUC-2 ex-
pression in SW480 colon cancer cells might also involve
CysLT2R signaling, as the effect can be reduced by either
a CysLT2R inhibitor or by RARα siRNA alone or a com-
bination of RARα and RARβ siRNA. Moreover, wefound that ATRA-induced alkaline phosphatase activity
could be reduced by pretreatment with the same
CysLT2R inhibitor. Our findings indicate that CysLT2R
signaling, likely in concert with other pathways, contrib-
utes to ATRA’s differentiation-inducing activity.
In addition to being a powerful differentiation-
inducing agent, ATRA can inhibit growth in some colon
cancer cell lines [48]. Therefore, we investigated whether
ATRA primarily affects differentiation in SW480 cells,
or also inhibits growth. In HT-29 cells ATRA-induced
growth inhibition is mediated by RARα [49], whereas, in
Caco-2 cells it is mediated by RARβ [50]. However,
other studies have reported that ATRA has no effect on
growth inhibition in HT-29 cells [27]. In certain con-
texts, ATRA also has the ability to mediate apoptosis
[35]. In our study, we were unable to observe any effects
of ATRA on growth inhibition or apoptosis in SW480
cells, suggesting that ATRA’s main activity in these cells
is to induce cell differentiation.
Although the CYSLTR2 gene has been mapped to
chromosome 13q14, a region linked to atopic asthma
[9], it remains unclear how the gene is regulated. When
studying the promoter region of CysLT2R, we found a
binding site for IRF-7 that showed reporter gene activity
upon IFNα stimulation [32]. This finding encouraged us
to further investigate whether other regulatory elements
in the region were present. This analysis led us to iden-
tify, for the first time, putative RARE elements in the
promoter region of CysLT2R. Stimulation with ATRA in-
creased CysLT2R promoter activity in a reporter gene
assay, but neither mutations nor truncations in the
RARE elements decreased the activity. In the present
study, we found a discrepancy between the regulation of
the endogenous CysLT2R gene activity and the regula-
tion of a transfected partial/putative promoter of the
same gene. At present we do not know the reason for
this discrepancy, but a couple of explanations can be
considered. First, the transfected CysLT2R promoter is
expressed at a level that in comparison with the en-
dogenous promoter is significantly higher and therefore
relatively low level of RARs do not have the same ability
to regulate its activity as they have when only the en-
dogenous promoter for CysLT2R is present. Secondly,
another possibility is that our transfected putative
CysLT2R promoter is lacking crucial bindings sites for
some enhancer/cofactor that is vital for its proper regu-
lation. Thirdly, in addition to direct ligand-dependent tran-
scription of genes, there can be indirect effects such
transactivation of other transcription factors independently
of any RAR and also non-genomic mechanisms of action
of ATRA [51]. Finally, our data might suggest that the ef-
fect of ATRA on CysLT2R promoter activity is indirect and
does not involve these putative RARs. Clearly, this issue
requires extensive future work before it can be resolved.
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promoters have focused on proteins involved in retinoid
transport or catabolism [52,53] or developmental regula-
tion, where ATRA is considered a ‘master switch’ for dif-
ferentiation. For example, ATRA induces hoxb1
expression, a gene responsible for gut development in
mouse embryos [54]. Other ATRA-induced transcription
factors or cofactors include STAT-1, Oct3/4, Hoxa1, and
Hoxb4 [53,55]. Retinoids also have the ability to repress
genes. In a mouse epidermal cell line, retinoids block
tumor promotion by inhibiting AP-1 [56]. Interestingly,
we previously observed that signaling through CysLT1R
induces activation of the AP-1 pathway in intestinal epi-
thelial cells, leading to increased proliferation [57]. Here
we show that expression of CysLT1R is unaffected by
ATRA treatment. High CysLT1R expression in cancer
patients is not restricted to colorectal cancer cells; it has
also been observed in transitional cell carcinoma of the
bladder [58], neuroblastoma [59], astrocytoma [60], and
in classical Hodgkin’s lymphoma [61]. ATRA’s mechan-
ism of action on cysteinyl leukotriene receptors may also
highlight a signaling pathway that contributes to other
cancer types.
We show for the first time that in human colon cancer
cells, the differentiation agent ATRA acts in part by in-
ducing both LTC4S, an enzyme responsible for the gen-
eration of CysLTs, and CysLT2R, a receptor for these
ligands. Furthermore, we report that this effect is very
likely mediated through RARα or a combination of
RARα and RARβ and presumably acts through a medi-
ator that can regulate CysLT2R. ATRA-induced differen-
tiation can partially be reduced by a CysLT2R inhibitor,
implying that CysLT2R contributes to this differentiation.
Finally, ATRA does not induce expression of the pro-
mitogenic CysLT1R.
Conclusions
We suggest here a mechanism by which ATRA induces
differentiation, in part by increasing CysLT2R expression.
Our data shed new light on how ATRA exerts its effects
on colorectal cancer cell differentiation and demon-
strates that retinoids are able to delicately regulate the
balance between different elements in the cysteinyl leu-
kotriene pathway. Further work is necessary to elucidate
the interplay between retinoids and eicosanoids, but the
knowledge gained from such studies could yield new in-
sights for designing colon cancer therapy regimens.
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